Worth reading
39Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
223575
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of stock acquisition rights (stock options) to directors (SymBio Pharmaceuticals Limited 68th Stock Acquisition Rights)
発行・処分する株式数
223,575 shares (8,943 stock acquisition rights)
Intended allottee
Name 5 directors of the Company (1 representative director and 4 outside directors who are not Audit & Supervisory Committee members) / Number of Shares Not disclosed
¥2,400 per stock acquisition right and ¥96 per share
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total issued: 8,943 stock acquisition rights; unexercised balance: Not disclosed
Categories and Number of Persons Covered
1 representative director and 4 outside directors who are not Audit & Supervisory Committee members, for a total of 5 people. The number of shares allotted by category is Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of stock acquisition rights (stock options) to directors (SymBio Pharmaceuticals Limited 68th Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | 223,575 shares (8,943 stock acquisition rights) |
| Issue price and disposal price | ¥2,400 per stock acquisition right and ¥96 per share |
| Intended allottee | Name 5 directors of the Company (1 representative director and 4 outside directors who are not Audit & Supervisory Committee members) / Number of Shares Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 8,943 stock acquisition rights; unexercised balance: Not disclosed |
| Categories and Number of Persons Covered | 1 representative director and 4 outside directors who are not Audit & Supervisory Committee members, for a total of 5 people. The number of shares allotted by category is Not disclosed |
Items this document does not state (22)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The previously undetermined items relating to the stock options resolved at the Board of Directors meeting held on 24 March 2026 have been finalized. The company explains that the issuance does not constitute an issuance on favorable terms.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.